The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros

Molecular Pharmacology

Volumn 87, Issue 6, 2015, Pages 996-1005

  Chen, Mei Chuan ^c   Zhou, Bingsen ^a   Zhang, Keqiang ^a   Yuan, Yate Ching ^a   Un, Frank ^a   Hu, Shuya ^a   Chou, Chih Ming ^d   Chen, Chun Han ^c   Wu, Jun ^a   Wang, Yan ^a   Liu, Xiyong ^a   Smith, D Lynne ^a   Li, Hongzhi ^a   Liu, Zheng ^a   Warden, Charles D ^a   Su, Leila ^a   Malkas, Linda H ^a   Chung, Young Min ^b   Hu, Mickey C T ^b   Yen, Yun ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; BRCA1 PROTEIN; GREEN FLUORESCENT PROTEIN; OXIDOREDUCTASE INHIBITOR; RAD51 PROTEIN; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; [N [4 (3,4 DIHYDROXYPHENYL) 5 PHENYLTHIAZOL 2 YL] 3,4 DIHYDROXYBENZAMIDE]; BENZAMIDE DERIVATIVE; N-(4-(3,4-DIHYDROXYPHENYL)-5-PHENYLTHIAZOL-2-YL)-3,4-DIHYDROXYBENZAMIDE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECOMBINATION REPAIR; REPORTER GENE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; DRUG EFFECTS; GENETICS; MUTAGEN TESTING; NONOBESE DIABETIC MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT; ZEBRA FISH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BENZAMIDES; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA END-JOINING REPAIR; DNA REPAIR; FEMALE; HETEROGRAFTS; HUMANS; MICE, INBRED NOD; MUTAGENICITY TESTS; NEOPLASM TRANSPLANTATION; RIBONUCLEOTIDE REDUCTASES; THIAZOLES; ZEBRAFISH;

EID: 84940054160     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.094987     Document Type: Article

References (38)

1. Abbas T, Keaton MA, and Dutta A (2013) Genomic instability in cancer. Cold Spring Harb Perspect Biol 5:a012914.
2. Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, and Ford JM (2011) Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells (Abstract). BMC Pharmacol 11:7.
3. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, and Eppig JT et al.; The Gene Ontology Consortium (2000) Gene ontology: tool for the unification of biology. Nat Genet 25:25-29.
4. Baumann P, Benson FE, and West SC (1996) Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87:757-766.
5. Benjamini Y and Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B 57:289-300.
6. Bennardo N, Cheng A, Huang N, and Stark JM (2008) Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 4:e1000110.
7. Chung YM, Park SH, Tsai WB, Wang SY, Ikeda MA, Berek JS, Chen DJ, and Hu MC (2012) FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage (Abstract). Nat Commun 3:1000.
8. Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12:801-817.
9. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, and Swisher EM (2007) Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res 5:35-45.
10. Deng CX and Brodie SG (2000) Roles of BRCA1 and its interacting proteins. Bio-Essays 22:728-737.
11. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, and Helleday T (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389-5398.
12. Haaf T, Golub EI, Reddy G, Radding CM, and Ward DC (1995) Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc Natl Acad Sci USA 92:2298-2302.
13. Hehlmann R (2003) Current CML therapy: progress and dilemma. Leukemia 17:1010-1012.
14. Helleday T, Petermann E, Lundin C, Hodgson B, and Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193-204.
15. Hu T, Chung YM, Guan M, Ma M, Ma J, Berek JS, and Hu MC (2014) Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation (Abstract). Sci Rep 4:5810.
16. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, and Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
17. Keshelava N, Frgala T, Krejsa J, Kalous O, and Reynolds CP (2005) DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110:139-153.
18. Lin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, Glazer PM, and Sartorelli AC (2011) Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol 80:1000-1012.
19. Lin ZP, Ratner ES, Whicker ME, Lee Y, and Sartorelli AC (2014) Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res 12:381-393.
20. Maugeri-Saccà M, Bartucci M, and De Maria R (2012) DNA damage repair pathways in cancer stem cells. Mol Cancer Ther 11:1627-1636.
21. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, and Chatterjee S et al. (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2:371-382.
22. Moeller BJ, Pasqualini R, and Arap W (2009) Targeting cancer-specific synthetic lethality in double-strand DNA break repair. Cell Cycle 8:1872-1876.
23. Petermann E, Orta ML, Issaeva N, Schultz N, and Helleday T (2010) Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 37:492-502.
24. Pierce AJ, Hu P, Han M, Ellis N, and Jasin M (2001) Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev 15:3237-3242.
25. Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358:1362-1369.
26. Reichard P and Ehrenberg A (1983) Ribonucleotide reductase: a radical enzyme. Science 221:514-519.
27. Riballo E, Kühne M, Rief N, Doherty A, Smith GC, Recio MJ, Reis C, Dahm K, Fricke A, and Krempler A et al. (2004) A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 16:715-724.
28. Schneider CA, Rasband WS, and Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675.
29. Shao J, Zhou B, Chu B, and Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409-431.
30. Shao J, Zhou B, Zhu L, Qiu W, Yuan YC, Xi B, and Yen Y (2004) In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 64:1-6.
31. Shewach DS and Lawrence TS (2007) Antimetabolite radiosensitizers. J Clin Oncol 25:4043-4050.
32. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, and Shay JW et al. (1998) Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 58:3237-3242.
33. Un F, Qi C, Prosser M, Wang N, Zhou B, Bronner C, and Yen Y (2006) Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity. Anticancer Res 26 (4B):2761-2767.
34. Westerfield M (1993) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Brachydanio rerio), M. Westerfield, Eugene, OR.
35. Wooster R and Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339-2347.
36. Xue L, Zhou B, Liu X, Qiu W, Jin Z, and Yen Y (2003) Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 63:980-986.
37. Young CW and Hodas S (1964) Hydroxyurea: Inhibitory Effect on DNA Metabolism. Science 146:1172-1174.
38. Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, and Synold TW et al. (2013) A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res 73:6484-6493.